Research Topics
Species | Stephanie k LeeSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chronic graft-versus-host diseaseStephanie J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 9:215-33. 2003..It also provides a comprehensive listing of the published clinical trials aimed at prevention and primary treatment of chronic GVHD...- Patient-reported outcomes in multiple myelomaStephanie J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
J Natl Compr Canc Netw 2:379-83. 2004..In multiple myeloma, several patient-reported measures have been used to enrich our understanding of the disease's impact on patients' lives and the risks and benefits of specific treatments... - New approaches for preventing and treating chronic graft-versus-host diseaseStephanie J Lee
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 105:4200-6. 2005..Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD... - Routine screening for psychosocial distress following hematopoietic stem cell transplantationS J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 35:77-83. 2005..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs... - Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantationStephanie J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 104:2194-200. 2004.... - Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialStephanie J Lee
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 104:1559-64. 2004..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD... - Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costsStephanie J Lee
Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Blood 100:2697-702. 2002..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention... - Development and validation of a scale to measure symptoms of chronic graft-versus-host diseaseStephanie k Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 8:444-52. 2002..The cGVHD symptom scale is a short, simple, and valid measure of cGVHD manifestations and can be used to follow complication-specific symptoms using patient self-administered questionnaires... - Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapseStephanie J Lee
Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
Blood 100:406-14. 2002..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression... - A survey of diagnosis, management, and grading of chronic GVHDStephanie J Lee
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 8:32-9. 2002..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD... - Predicting costs of stem-cell transplantationS J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
J Clin Oncol 18:64-71. 2000..We sought (1) to determine whether obtaining baseline information enabled identification of patients whose treatments would be the most costly and (2) to estimate inpatient costs for managing specific transplantation complications... - Outcomes research in oncology: history, conceptual framework, and trends in the literatureS J Lee
Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 92:195-204. 2000..We suggest that as different branches of investigation develop their own literature and methodology-in effect, outgrowing the generic label of outcomes research-they become identified by separate, more precise terms... - Discrepancies between patient and physician estimates for the success of stem cell transplantationS J Lee
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
JAMA 285:1034-8. 2001..Stem cell transplantation is associated with considerable morbidity and mortality. The extent to which patients and their physicians correctly estimate these risks is unknown... - Chronic myelogenous leukaemiaS J Lee
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Br J Haematol 111:993-1009. 2000..Clinical and laboratory science seems poised to add novel therapies to the armamentarium against CML. It is exciting to contemplate what reviews of CML written 10 years from now will discuss... - Recovery after stem-cell transplantation for hematologic diseasesS J Lee
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:242-52. 2001.... - The effect of thrombin on ACL fibroblast interactions with collagen hydrogelsM M Murray
Department of Orthopaedic Surgery, Children s Hospital of Boston, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
J Orthop Res 24:508-15. 2006..Use of low concentrations of thrombin (10.5 IU/mL) may be beneficial in applications where a faster set time and enhanced cell migration are desirable and the gel mechanical strength is of secondary importance... - Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantationD J Andorsky
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
Bone Marrow Transplant 37:889-95. 2006..Measurement of baseline QOL can help place the effects of the transplantation procedure in context... - HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantationV T Ho
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 37:845-50. 2006..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST... - Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancyA M Saito
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 40:209-17. 2007..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures... - Early cervical adenocarcinoma: selection criteria for radical surgeryJ O Schorge
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, Massachusetts, 02115, USA
Obstet Gynecol 94:386-90. 1999..To identify selection criteria for radical surgery in early cervical adenocarcinoma based on pretreatment clinical stage and correlation with high-risk surgical-pathologic factors... - The impact of risk information on patients' willingness to pay for autologous blood donationS J Lee
Division of Hematology Oncology, Brigham and Women s Hospital, Boston, MA, USA
Med Care 36:1162-73. 1998.... - Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host diseaseV T Ho
Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 34:987-94. 2004..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD... - Modelling the early detection of breast cancerS J Lee
Dana Farber Cancer Institute and the Harvard School of Public Health, Boston, MA 02115, USA
Ann Oncol 14:1199-202. 2003..The theoretical model is general and may be applied to other chronic diseases, which satisfy the basic assumptions... - The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phaseS J Lee
Chronic Leukemia Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Blood 98:3205-11. 2001..In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation... - Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantationV T Ho
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 7:223-9. 2001..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs... - A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantationJ H Antin
Department of Adult Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Bone Marrow Transplant 29:373-7. 2002..The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial... - Quality of life associated with acute and chronic graft-versus-host diseaseS J Lee
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Bone Marrow Transplant 38:305-10. 2006..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL... - Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant ResearcJ D Rizzo
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
Bone Marrow Transplant 37:249-61. 2006....